Muscle Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MSC072 MIFTS: 48	Muscle Cancer Categories: Cancer diseases, Muscle diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Muscle Cancer

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer ¹² ⁵⁴ ¹⁵ ¹⁷

Myosarcoma ¹² ⁵⁴ ⁴⁴ ⁷¹

Malignant Neoplasm of Muscle ¹² ⁷¹

Malignant Tumor of the Muscle ¹²

Malignant Tumor of Muscle ¹²

Myomatous Neoplasm ⁷¹

Muscle Neoplasms ⁴⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Muscle diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of other connective and soft tissue

External Ids:

Disease Ontology ¹² DOID:4045

MeSH ⁴⁴ D009217 D019042

NCIt ⁵⁰ C4883

SNOMED-CT ⁶⁷ 20667008 93913006

ICD10 ³² C49

EFO ¹⁷ EFO_0007384

UMLS ⁷¹ C0027095 C0282606 C0684743

Sources

Summaries for Muscle Cancer

Disease Ontology : ¹² A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to myoma and leiomyosarcoma, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and C-MYB transcription factor network. The drugs Pembrolizumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include muscle, liver and uterus, and related phenotypes are integument and muscle

Wikipedia : ⁷⁴ A soft-tissue sarcoma (STS) is a malignant tumour, a type of cancer, that develops in soft tissue. A... more...

Sources

Related Diseases for Muscle Cancer

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)

#	Related Disease	Score	Top Affiliating Genes
1	myoma	32.3	TP53 KIT CD34 CALD1
2	leiomyosarcoma	31.9	TP53 SERPINA3 MYOG KIT DES
3	rhabdomyosarcoma	31.7	TP53 PAX7 PAX3 MYOG MYOD1 KIT
4	skeletal muscle cancer	31.7	TP53 TFE3 SERPINA3 RHD PAX7 PAX3
5	cutaneous leiomyosarcoma	30.8	DES CD34 CALD1
6	sarcoma	30.7	TP53 TFE3 MYOG KIT EWSR1 ASPSCR1
7	spindle cell sarcoma	30.7	SERPINA3 MYOG KIT EWSR1 DES CD34
8	smooth muscle tumor	30.6	SERPINA3 KIT DES CD34 CALD1
9	intravenous leiomyomatosis	30.6	DES CD34 CALD1
10	botryoid rhabdomyosarcoma	30.6	PAX3 MYOG MYOD1 DES
11	infantile myofibromatosis	30.6	DES CD34 CALD1
12	fibrosarcoma	30.5	TP53 KIT EWSR1 DES
13	hemangiopericytoma, malignant	30.4	SERPINA3 MYOG KIT DES CD34 CALD1
14	angiomyolipoma	30.3	TFE3 KIT DES
15	carcinosarcoma	30.3	TP53 KIT DES
16	vulvar leiomyoma	30.3	CD34 CALD1
17	bizarre leiomyoma	30.3	TP53 CALD1
18	bladder leiomyoma	30.2	MYOD1 KIT EWSR1 CD34 CALD1
19	embryonal rhabdomyosarcoma	30.2	TP53 PAX7 PAX3 MYOG MYOD1 FOXO1
20	endometrial stromal sarcoma	30.2	TP53 KIT EWSR1 DES CALD1
21	mesenchymal cell neoplasm	30.0	TP53 TFE3 SERPINA3 MYOG MIR199A1 KIT
22	striated muscle rhabdoid tumor	10.8
23	central nervous system rhabdomyosarcoma	10.6	PAX3 FOXO1
24	ovarian fibrothecoma	10.6	KIT DES
25	lung combined type small cell carcinoma	10.6	MYOG CALD1
26	urethra leiomyoma	10.6	KIT CALD1
27	fibroma	10.6	SERPINA3 DES CD34
28	congenital epulis	10.6	SERPINA3 DES
29	spinal cord sarcoma	10.6	KIT CD34
30	gallbladder sarcoma	10.6	MYOG MYOD1 DES
31	extraskeletal chondroma	10.6	SERPINA3 EWSR1
32	malignant triton tumor	10.6	MYOG MYOD1 DES
33	intravascular angioleiomyoma	10.6	CD34 CALD1
34	skeletal muscle neoplasm	10.6	RHD MYOG MYOD1
35	gallbladder leiomyoma	10.6	KIT CD34
36	breast myofibroblastoma	10.6	CD34 CALD1
37	scrotum neoplasm	10.5	SERPINA3 MYOG
38	pineal region teratoma	10.5	MYOG MYOD1 KIT
39	gas gangrene	10.5	SERPINA3 MYOG MYOD1
40	small intestine leiomyosarcoma	10.5	KIT CD34
41	extraosseous ewing sarcoma	10.5	MYOG MYOD1 EWSR1
42	spermatic cord cancer	10.5	MYOD1 CD34
43	neuronal intestinal dysplasia, type b	10.5	KIT CD34
44	malignant epithelioid hemangioendothelioma	10.5	TFE3 SERPINA3
45	glomangiomyoma	10.5	CD34 CALD1
46	glomangioma	10.5	DES CD34 CALD1
47	adult cystic nephroma	10.5	KIT DES
48	prostate rhabdomyosarcoma	10.5	MYOG MYOD1
49	ectomesenchymoma	10.5	PAX3 MYOG FOXO1 DES
50	extracranial neuroblastoma	10.5	MYOG EWSR1

Graphical network of the top 20 diseases related to Muscle Cancer:

Sources

Symptoms & Phenotypes for Muscle Cancer

UMLS symptoms related to Muscle Cancer:

muscle weakness, myoclonus, myalgia, torticollis, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Muscle Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	integument	MP:0010771	9.91	CD34 FOXO1 KIT MYOG PAX3 PAX7
2	muscle	MP:0005369	9.76	DES FOXO1 KIT MYOD1 MYOG PAX3
3	neoplasm	MP:0002006	9.5	CD34 FOXO1 KIT MYOD1 PAX3 PAX7
4	no phenotypic analysis	MP:0003012	9.17	FOXO1 KIT MYOD1 MYOG PAX3 PAX7

Sources

Drugs & Therapeutics for Muscle Cancer

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pembrolizumab

Approved

Phase 3

1374853-91-4

Cisplatin

Approved

Phase 3

15663-27-1

84093 441203 2767

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

Carboquone

CDDP

CHEBI:35852

CID441203

Cis Pt II

cis-[PtCl2(NH3)2]

cis-DDP

Cis-DDP

Cis-Diaminedichloroplatinum

cis-diamminedichloridoplatinum(II)

cis-Diamminedichloroplatinum

Cis-Diamminedichloroplatinum

cis-diamminedichloroplatinum(II)

cis-Dichlorodiammineplatinum(II)

Cismaplat

Cisplatin

Cisplatine

cisplatino

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

CPD0-1392

CPDC

CPDD

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

nchembio773-comp1

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

trans-DDP

Trans-DDP

Trans-Diaminedichloroplatinum

trans-diamminedichloridoplatinum(II)

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

Gemcitabine

Approved

Phase 3

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DFDC

2',2'-DiF-dC

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate

2'-Deoxy-2'-difluorocytidine

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFdC

DFDC

DFdCyd

Folfugem

Gamcitabine

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

gemcitabine

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer

Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Gemcitabine, (D-threo-pentafuranosyl)-isomer

Gemcitabinum

Gemcitabinum [INN-Latin]

GemLip

Gemtro

Gemzar

Gemzar (hydrochloride)

GEO

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY188011

LY-188011

NCGC00168784-01

NChemBio.2007.10-comp25

nchembio.573-comp7

nchembio.90-comp2

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

Zefei

ZINC18279854

Immunosuppressive Agents

Phase 3

Immunologic Factors

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Anti-Infective Agents

Phase 3

Antimetabolites

Phase 3

Antiviral Agents

Phase 3

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Synonyms:

(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid

(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid

148-82-3

3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine

3025 c.b

3025 C.B.

3223-07-2

3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine

4-(Bis(2-chloroethyl)amino)-L-phenylalanine

4-(Bis(2-chloroethyl)amino)phenylalanine

4-[Bis(2-chloroethyl)amino]-L-phenylalanine

4-[Bis-(2-chloroethyl)amino]-L-phenylalanine

4-14-00-01689 (Beilstein Handbook Reference)

AC1LA2OE

Alanine Nitrogen Mustard

Alkeran

ALKERAN (TN)

AmbotzHAA1563

At-290

AY3360000

BIDD:GT0044

BRD-K87827419-001-02-8

BRN 2816456

BSPBio_002407

C13H18Cl2N2O2

CB 3025

CB-3025

CCRIS 374

CHEBI:165415

CHEBI:28876

CHEMBL852

CID460612

D00369

DivK1c_000653

EINECS 205-726-3

HMS2090B09

HMS2091B16

HMS502A15

HSDB 3234

IDI1_000653

KBio1_000653

KBio2_000877

KBio2_003445

KBio2_006013

KBio3_001627

KBioGR_001284

KBioSS_000877

L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine

Levofalan

Levofolan

Levopholan

L-PAM

L-Phenylalanine mustard

LS-15868

LS-865

L-Sarcolysin

L-Sarcolysine

L-Sarkolysin

M2011_SIGMA

Medphalan

Melfalan

Melfalano

Melfalano [INN-Spanish]

melphalan

Melphalan

Melphalan (JP15/USP/INN)

MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))

Melphalan [USAN:INN:BAN:JAN]

Melphalanum

Melphalanum [INN-Latin]

Mephalan

Merphalan

MLS001333666

MLS002153368

MolPort-003-665-535

Mustard, phenylalanine

NCGC00090757-01

NCGC00090757-02

NCGC00090757-03

NCI-C04853

NINDS_000653

NIOSH/AY3360000

NSC 241286

NSC 8806

NSC241286

NSC8806

NSC-8806

p-Bis(b-chloroethyl)aminophenylalanine

p-Bis(beta-chloroethyl)aminophenylalanine

p-Bis(β-chloroethyl)aminophenylalanine

p-Di-(2-chloroethyl)amino-L-phenylalanine

Phenylalanine mustard

phenylalanine nitrogen mu stard

Phenylalanine nitrogen mustard

p-L-Sarcolysin

p-L-sarcolysine

p-N,N-bis(2-chloroethyl)amino-L-phenylalanine

p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-di(chloroethyl)aminophenylala nine

p-N-Di(chloroethyl)aminophenylalanine

Prestwick_1006

RCRA waste no. U150

Rcra waste number U150

Sarcolysine

Sarkolysin

SK-15673

SMP2_000174

SMR000058720

SPBio_000287

Spectrum_000397

SPECTRUM1500382

Spectrum2_000074

Spectrum3_000684

Spectrum4_000882

Spectrum5_001601

TL8001065

TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)

TRANSGENIC MODEL EVALUATION (MELPHALAN)

UNII-Q41OR9510P

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-hydroxydaunomycin

14-Hydroxydaunomycin

14-hydroxydaunorubicine

14-Hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

adiblastine (hydrochloride salt)

ADM

ADR

adr iablatina (hydrochloride salt)

Adriablastin

Adriablastine

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin semiquinone

Adriamycin Semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (hydrochloride salt)

Adriblastina (TN)

Adriblastine

adriblatina (hydrochloride salt)

Adrimedac

Aerosolized Doxorubicin

Baxter brand OF doxorubicin hydrochloride

Bedford brand OF doxorubicin hydrochloride

BPBio1_000502

BRD-K92093830-003-04-3

Bristol-myers squibb brand OF doxorubicin hydrochloride

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

Caelyx

CCRIS 739

Cell pharm brand OF doxorubicin hydrochloride

CHEBI:28748

CHEMBL179

CID31703

Columbia brand OF doxorubicin hydrochloride

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

Doxil

Doxo

Doxo cell

Doxo-cell

Doxolem

doxorubicin

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin HCl

Doxorubicin hexal

Doxorubicin hydrochloride

Doxorubicin Hydrochloride

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin NC

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicina ferrer farm

Doxorubicina funk

Doxorubicina tedec

Doxorubicine

Doxorubicine [INN-French]

Doxorubicine baxter

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicinum

Doxorubicinum [INN-Latin]

Doxotec

DOX-SL

EINECS 245-495-6

Elan brand OF doxorubicin hydrochloride

Farmablastina (hydrochloride salt)

Farmiblastina

Ferrer brand OF doxorubicin hydrochloride

FI 106

Hexal brand OF doxorubicin hydrochloride

HMS2089H06

HSDB 3070

Hydrochloride, doxorubicin

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

Kenfarma brand OF doxorubicin hydrochloride

Lemery brand OF doxorubicin hydrochloride

LMPK13050001

LS-1029

LS-165655

Medac brand OF doxorubicin hydrochloride

MLS000759533

Myocet

NChemBio.2007.10-comp13

nchembio809-comp5

NCI-C01514

NDC 38242-874

Neocorp brand OF doxorubicin hydrochloride

NIOSH/JT9100000

NSC 123127

Onkodox

Onkoworks brand OF doxorubicin hydrochloride

Pfizer brand OF doxorubicin hydrochloride

Prasfarma brand OF doxorubicin hydrochloride

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Ribodoxo

Ribosepharm brand OF doxorubicin hydrochloride

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

Tedec meiji brand OF doxorubicin hydrochloride

ThermoDox

TLC D-99

Triferric doxorubicin

UNII-80168379AG

Urokit doxo cell

Urokit doxo-cell

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Synonyms:

1-THIOETHANEsulfonate

1-THIOETHANEsulfonIC ACID

1-THIOETHANEsulphonate

1-THIOETHANEsulphonic acid

2 Mercaptoethanesulfonate

2-Mercaptoethane

2-Mercaptoethanesulfonate

2-mercaptoethanesulfonic acid

2-Mercaptoethanesulfonic acid

2-Mercaptoethanesulphonate

2-Mercaptoethanesulphonate, sodium

2-mercaptoethanesulphonic acid

2-Mercaptoethanesulphonic acid

2-mercaptoethylsulfonate

2-Mercaptoethylsulfonate

2-Mercaptoethylsulfonic acid

2-Mercaptoethylsulphonate

2-Mercaptoethylsulphonic acid

2-sulfanylethylsulfonate

2-Sulfanylethylsulfonate

2-Sulfanylethylsulfonic acid

2-Sulphanylethylsulphonate

2-Sulphanylethylsulphonic acid

ASTA D 7093

ASTA medica brand OF mesna

ASTAD 7093

ASTA-D 7093

beta-Mercaptoethanesulfonate

beta-Mercaptoethanesulfonic acid

beta-Mercaptoethanesulphonate

beta-Mercaptoethanesulphonic acid

b-Mercaptoethanesulfonate

b-Mercaptoethanesulfonic acid

b-Mercaptoethanesulphonate

b-Mercaptoethanesulphonic acid

Bristol myers squibb brand OF mesna

Bristol-myers squibb brand OF mesna

Cell pharm brand OF mesna

Coenzima m

Coenzima M

Coenzym m

Coenzym M

Coenzyme m

CoM

HS-CoM

Kendrick brand OF mesna

Mesna

MESNA cell

Mesna kendrick brand

Mesna sanfer brand

MESNA-cell

Mesnex

Mesnum

Mistabron

Mistabronco

Mitexan

Mucofluid

reduced coenzyme M

Reduced coenzyme m

reduced CoM

Reduced com

Sanfer brand OF mesna

Sodium 2-mercaptoethanesulphonate

UCB brand OF mesna

Uromitexan

Ziken

Β-mercaptoethanesulfonate

β-mercaptoethanesulfonic acid

Β-mercaptoethanesulfonic acid

Β-mercaptoethanesulphonate

Β-mercaptoethanesulphonic acid

Ifosfamide

Approved

Phase 2

3778-73-2

3690

Synonyms:

(+-)-Ifosfamid

(+-)-Ifosphamide

(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

(D,L)-Ifosfamide

(R,S)-Ifosphamide

(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3,} 2-oxazaphosphorine oxide

36341-88-5

3778-73-2

84711-20-6

A 4942

AB00513932

AC1L1GHW

AC-2113

Ambap3778-73-2

Asta Z 4942

ASTA Z 4942

BPBio1_000865

BRN 0611835

BSPBio_000785

C07047

CAS-3778-73-2

CCRIS 352

CHEBI:5864

CHEMBL1024

CID3690

Cyfos

D00343

D007069

DB01181

EINECS 223-237-3

HMS1570H07

HMS2090M12

HMS2093N07

Holoxan

Holoxan 1000

HSDB 7023

I06-0494

Ifex

IFEX (TN)

Ifosfamid

Ifosfamida

Ifosfamida [INN-Spanish]

ifosfamide

Ifosfamide

Ifosfamide (JAN/USP/INN)

Ifosfamide [USAN:INN:BAN:JAN]

Ifosfamide sterile

Ifosfamide Sterile

Ifosfamidum

Ifosfamidum [INN-Latin]

Ifosphamide

Ifsofamide

Iphosphamid

Iphosphamid(e)

Iphosphamide

I-phosphamide

I-Phosphamide

Iso endoxan

Iso Endoxan

Isoendoxan

Iso-endoxan

Iso-Endoxan

Isofosfamide

Isophosphamide

isosfamide

Isosfamide

LS-102

LS-99799

Mitoxana

Mitoxana, Ifex, Ifosfamide

MJF 9325

MJF-9325

MLS002154021

MolPort-003-666-704

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide

N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide

Naxamide

NCGC00016639-01

NCGC00179435-01

NCI60_000233

NCI-C01638

NPFAPI-04

NSC 109,724

NSC 109724

NSC109,724

NSC-109,724

NSC109724

NSC-109724

Prestwick0_000833

Prestwick1_000833

Prestwick2_000833

Prestwick3_000833

S1302_Selleck

SMR001233348

SPBio_002706

STL058690

UNII-UM20QQM95Y

WLN: T6NPOTJ AM2G BO B2G

Z 4942

Z4942

Z-4942

Alkylating Agents

Phase 2

Liposomal doxorubicin

Phase 2

31703

Isophosphamide mustard

Phase 2

100427

Synonyms:

Ifosfamide mustard

Ifosforamide mustard

IPAM

Iphosphoramide mustard

Isophosphamide mustard

Isophosphoramide mustard

N,N'-di-(2-chloroethyl)phosphorodiamidic acid

NN'-Bis-(2-chloroethyl)phosphate

NN'-Bis-(2-chloroethyl)phosphoric acid

Palifosfamide

Palifosfamide-tris

Zio-201isophosphamide mustard

Antibiotics, Antitubercular

Phase 1

Liver Extracts

Phase 1

Anti-Bacterial Agents

Phase 1

Cola

Phase 1

Analgesics, Non-Narcotic

Phase 1

Interleukin-2

Phase 1

Vaccines

Phase 1

Analgesics

Phase 1

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Cisplatin-Ineligible Participants With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)	Recruiting	NCT03924895	Phase 3	Pembrolizumab;Enfortumab Vedotin
2	A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)	Recruiting	NCT03924856	Phase 3	Pembrolizumab;Gemcitabine;Cisplatin;Placebo
3	Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity	Completed	NCT00019968	Phase 2	melphalan;tumor necrosis factor
4	Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	Active, not recruiting	NCT03651375	Phase 2	Sequential chemotherapy - 3 courses of AI
5	Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors	Completed	NCT00019630	Phase 1	doxorubicin HCl liposome
6	Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen	Completed	NCT00020267	Phase 1	interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
7	Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study	Completed	NCT02380651

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Sources

Genetic Tests for Muscle Cancer

Sources

Anatomical Context for Muscle Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Muscle Cancer:

¹⁹

Muscle

MalaCards organs/tissues related to Muscle Cancer:

⁴⁰

Liver, Uterus, Skeletal Muscle, Skin, Colon, Kidney, Prostate

Sources

Publications for Muscle Cancer

Articles related to Muscle Cancer:

(show top 50) (show all 134)

#	Title	Authors	PMID	Year
1	New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. ⁶¹ ⁵⁴	Keller C...Capecchi MR	16140913	2005
2	Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract. ⁵⁴ ⁶¹	Watanabe K...Suzuki T	11473460	2001
3	Tenosynovial giant cell tumors: evidence for a desmin-positive dendritic cell subpopulation. ⁶¹ ⁵⁴	Folpe AL...Gown AM	9796719	1998
4	From Bench to Bedside in Tongue Muscle Cancer Invasion and Back again: Gross Anatomy, Microanatomy, Surgical Treatments and Basic Research. ⁶¹	Calabrese L...Lo Muzio L	32932638	2020
5	Opposing effects of 25-hydroxy- and 1α,25-dihydroxy-vitamin D3 on pro-cachectic cytokine-and cancer conditioned medium-induced atrophy in C2C12 myotubes. ⁶¹	Sustova H...Filigheddu N	30834670	2019
6	Diagnostic immunohistochemistry for canine cutaneous round cell tumours - retrospective analysis of 60 cases. ⁶¹	Pazdzior-Czapula K...Otrocka-Domagala I	31553052	2019
7	Effect of Ninjin'yoeito on the Loss of Skeletal Muscle Function in Cancer-Bearing Mice. ⁶¹	Ohsawa M...Ishikura KI	30555329	2018
8	Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. ⁶¹	Elufioye TO...Moody JO	28250653	2017
9	Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. ⁶¹	Bernard A...Pompei R	26071135	2015
10	Differential cytotoxic properties of Helleborus niger L. on tumour and immunocompetent cells. ⁶¹	Schink M...Grundemann C	25446603	2015
11	Application experience of intraoperative neuromonitoring in thyroidectomy. ⁶¹	Zheng H...Xu J	26885214	2015
12	YAPping about differentiation therapy in muscle cancer. ⁶¹	Svalina MN...Keller C	25117705	2014
13	Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. ⁶¹	Sokolowski E...Keller C	23665679	2014
14	The not-so-skinny on muscle cancer. ⁶¹	Kikuchi K...Keller C	23079652	2012
15	Mouse models of sarcomas: critical tools in our understanding of the pathobiology. ⁶¹	Post SM	23036318	2012
16	AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. ⁶¹	Jothi M...Mal AK	22333587	2012
17	Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. ⁶¹	Zhang Y...Wang C	21423212	2011
18	Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. ⁶¹	Lee MH...Mal AK	21493592	2011
19	Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. ⁶¹	Abraham J...Keller C	21447712	2011
20	Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs. ⁶¹	Jadi RS...Mishra AC	20716815	2010
21	Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ⁶¹	Stephens NA...Timmons JA	20193046	2010
22	A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. ⁶¹	Koh DI...Hur MW	19491398	2009
23	Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. ⁶¹	Nishijo K...Keller C	19339268	2009
24	MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. ⁶¹	Yang Z...Tapscott SJ	19299559	2009
25	Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing. ⁶¹	Chen HY...Lai PS	18923454	2009
26	PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. ⁶¹	Taniguchi E...Keller C	18679424	2008
27	[Non-epithelial tumors of the large intestine]. ⁶¹	Lewandowski A...Tabola R	19172837	2008
28	A new model for muscle cancer. ⁶¹		17585343	2007
29	Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. ⁶¹	Zhang L...Wang C	16964289	2007
30	The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. ⁶¹	Yu Y...Merlino G	16488997	2006
31	Malignancy-induced autoimmunity to MUC1: initial antibody characterization. ⁶¹	Graves CR...Chapman CJ	16316451	2005
32	Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. ⁶¹	Kirova YM...Fourquet A	15981282	2005
33	Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. ⁶¹	Keller C...Capecchi MR	15489287	2004
34	New chromanone acids with antibacterial activity from Calophyllum brasiliense. ⁶¹	Cottiglia F...Heilmann J	15104480	2004
35	Cytotoxic effects of some animal and vegetable extracts and some chemicals on liver and colon carcinoma and myosarcoma. ⁶¹	Bayazit V	14968209	2004
36	Synergistic effects of adenosine A1 and P2Y receptor stimulation on calcium mobilization and PKC translocation in DDT1 MF-2 cells. ⁶¹	Fredholm BB...Saito N	12825834	2003
37	In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. ⁶¹	Sciacca L...Belfiore A	12447687	2002
38	Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. ⁶¹	Eralp Y...Onat H	12151977	2002
39	Successful resection of a re-occurred pulmonary myosarcoma in a patient with turner syndrome mosaic. ⁶¹	Brauer VF...Schauer J	18521351	2002
40	Modification of hemostatic status improves antitumor efficiency of photodynamic therapy. ⁶¹	Zyablitskii VM...Panarina LV	11427917	2001
41	[Primitive leiomyosarcoma of the right atrium presenting with a pulmonary embolism]. ⁶¹	Imbert S...Roudaut R	10830098	2000
42	Aggressive congenital fibromatosis of the small intestine in the newborn. Report of a case and review of the literature. ⁶¹	Dessanti A...Dettori G	10661858	1999
43	Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. ⁶¹	Vassal G...Gouyette A	9615866	1998
44	[Bladder leiomyosarcoma. Report of a new case]. ⁶¹	Sanchez Gomez E	9065095	1996
45	Retrorectal tumors complicating pregnancy. Report of two cases. ⁶¹	Sobrado CW...Habr-Gama A	8831537	1996
46	[Antithrombogenic activity of blood vessel walls in the pathogenesis of metastasis in tumor-bearing animals]. ⁶¹	Liubina LV...Ziablitskii VM	8966053	1996
47	Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity. ⁶¹	Masegi T...Niitsu Y	7737913	1995
48	Radioimmunoscintigraphy using [111In]antimyosin Fab fragments for the diagnosis and follow-up of rhabdomyosarcoma. ⁶¹	Hoefnagel CA...Voute PA	8297646	1993
49	Myofibromatosis-like hemangiopericytoma metastasizing as differentiated vascular smooth-muscle and myosarcoma. Myopericytes as a subset of "myofibroblasts". ⁶¹	Dictor M...Ferno M	1463097	1992
50	Angiomatoid "malignant fibrous histiocytoma": an immunohistochemical study indicative of myoid differentiation. ⁶¹	Fletcher CD	1650754	1991

Sources

Genes for Muscle Cancer

Genes related to Muscle Cancer (0 elite genes):

(show top 50) (show all 52)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PAX3	Paired Box 3	Protein Coding	19.91	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	16140913
2	FOXO1	Forkhead Box O1	Protein Coding	19.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	16140913
3	MYOG	Myogenin	Protein Coding	17.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11473460 9796719
4	SERPINA3	Serpin Family A Member 3	Protein Coding	10.81	DISEASES inferred ¹⁵ ¹⁵
5	MIR675	MicroRNA 675	RNA Gene	8.99	DISEASES inferred ¹⁵ ¹⁵
6	DES	Desmin	Protein Coding	8.84	Novoseek inferred ⁵⁴	9796719
7	PAX7	Paired Box 7	Protein Coding	8.76	DISEASES inferred ¹⁵
8	MIR199A1	MicroRNA 199a-1	RNA Gene	8.66	DISEASES inferred ¹⁵ ¹⁵
9	MYOD1	Myogenic Differentiation 1	Protein Coding	8.63	DISEASES inferred ¹⁵
10	RHD	Rh Blood Group D Antigen	Protein Coding	8.51	DISEASES inferred ¹⁵
11	EWSR1	EWS RNA Binding Protein 1	Protein Coding	8.32	DISEASES inferred ¹⁵
12	CALD1	Caldesmon 1	Protein Coding	8.28	DISEASES inferred ¹⁵
13	MIR183	MicroRNA 183	RNA Gene	8.21	DISEASES inferred ¹⁵ ¹⁵
14	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	8.18	DISEASES inferred ¹⁵
15	MIR378A	MicroRNA 378a	RNA Gene	8.14	DISEASES inferred ¹⁵ ¹⁵
16	ASPSCR1	ASPSCR1 Tether For SLC2A4, UBX Domain Containing	Protein Coding	8.06	DISEASES inferred ¹⁵
17	CD34	CD34 Molecule	Protein Coding	7.99	DISEASES inferred ¹⁵
18	TFE3	Transcription Factor Binding To IGHM Enhancer 3	Protein Coding	7.96	DISEASES inferred ¹⁵
19	TP53	Tumor Protein P53	Protein Coding	7.92	DISEASES inferred ¹⁵
20	MIR9-1	MicroRNA 9-1	RNA Gene	7.91	DISEASES inferred ¹⁵ ¹⁵
21	H2AC18	H2A Clustered Histone 18	Protein Coding	7.84	DISEASES inferred ¹⁵ ¹⁵
22	MB	Myoglobin	Protein Coding	7.76	DISEASES inferred ¹⁵
23	SSX2	SSX Family Member 2	Protein Coding	7.44	DISEASES inferred ¹⁵
24	IGF2	Insulin Like Growth Factor 2	Protein Coding	7.43	DISEASES inferred ¹⁵
25	MDM2	MDM2 Proto-Oncogene	Protein Coding	7.41	DISEASES inferred ¹⁵
26	CD99	CD99 Molecule (Xg Blood Group)	Protein Coding	7.41	DISEASES inferred ¹⁵
27	PTCH1	Patched 1	Protein Coding	7.37	DISEASES inferred ¹⁵
28	ENO2	Enolase 2	Protein Coding	7.33	DISEASES inferred ¹⁵
29	SS18	SS18 Subunit Of BAF Chromatin Remodeling Complex	Protein Coding	7.26	DISEASES inferred ¹⁵
30	ANO1	Anoctamin 1	Protein Coding	7.2	DISEASES inferred ¹⁵
31	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	7.19	DISEASES inferred ¹⁵
32	MIR485	MicroRNA 485	RNA Gene	7.19	DISEASES inferred ¹⁵ ¹⁵
33	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	7.18	DISEASES inferred ¹⁵
34	NF1	Neurofibromin 1	Protein Coding	7.18	DISEASES inferred ¹⁵
35	SSX1	SSX Family Member 1	Protein Coding	7.16	DISEASES inferred ¹⁵
36	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	7.16	DISEASES inferred ¹⁵
37	MYF5	Myogenic Factor 5	Protein Coding	7.15	DISEASES inferred ¹⁵
38	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	7.15	DISEASES inferred ¹⁵
39	MYF6	Myogenic Factor 6	Protein Coding	7.13	DISEASES inferred ¹⁵
40	GLI1	GLI Family Zinc Finger 1	Protein Coding	7.11	DISEASES inferred ¹⁵
41	MIR342	MicroRNA 342	RNA Gene	7.1	DISEASES inferred ¹⁵ ¹⁵
42	MIR196A1	MicroRNA 196a-1	RNA Gene	7.1	DISEASES inferred ¹⁵ ¹⁵
43	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	7.08	DISEASES inferred ¹⁵
44	MLANA	Melan-A	Protein Coding	7.08	DISEASES inferred ¹⁵
45	MIR142	MicroRNA 142	RNA Gene	7.06	DISEASES inferred ¹⁵ ¹⁵
46	RMST	Rhabdomyosarcoma 2 Associated Transcript	RNA Gene	7.03	DISEASES inferred ¹⁵
47	SYP	Synaptophysin	Protein Coding	7.03	DISEASES inferred ¹⁵
48	CDK4	Cyclin Dependent Kinase 4	Protein Coding	6.97	DISEASES inferred ¹⁵
49	FGFR4	Fibroblast Growth Factor Receptor 4	Protein Coding	6.97	DISEASES inferred ¹⁵
50	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.92	DISEASES inferred ¹⁵

Sources

Variations for Muscle Cancer

Cosmic variations for Muscle Cancer:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM95516578	H3-3A	soft tissue,bone,sarcoma,NS	c.103G>T	p.G35W	1:226064454-226064454	3
2	COSM95520543	H3-3A	soft tissue,bone,sarcoma,NS	c.103G>T	p.G35W	1:226064454-226064454	3
3	COSM95523461	H3-3A	soft tissue,bone,sarcoma,NS	c.103G>T	p.G35W	1:226064454-226064454	3
4	COSM95526780	H3-3A	soft tissue,bone,sarcoma,NS	c.103G>T	p.G35W	1:226064454-226064454	3
5	COSM87494413	GNAQ	soft tissue,bone,sarcoma,NS	c.442C>T	p.R148*	9:77815650-77815650	3

Sources

Expression for Muscle Cancer

Search GEO for disease gene expression data for Muscle Cancer.

Sources

Pathways for Muscle Cancer

Pathways related to Muscle Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Transcriptional misregulation in cancer ³⁶	11.78	TP53 TFE3 PAX7 PAX3 FOXO1 EWSR1
2	C-MYB transcription factor network ¹	11.44	MYOD1 KIT CD34
3	Regulation of nuclear SMAD2/3 signaling ¹	11.38	TFE3 MYOD1 FOXO1
4	Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁴	11.15	PAX7 PAX3 MYOG MYOD1 KIT DES
5	Signaling events mediated by HDAC Class III ¹	11.02	TP53 MYOD1 FOXO1
6	Cell Differentiation - Index ¹	10.91	MYOD1 MIR9-1 MIR199A1

Sources

GO Terms for Muscle Cancer

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin	GO:0000785	9.17	TP53 TFE3 PAX7 PAX3 MYOG MYOD1

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of transcription by RNA polymerase II	GO:0006357	9.92	TP53 TFE3 PAX7 PAX3 MYOG MYOD1
2	gene silencing by miRNA	GO:0035195	9.83	MIR9-1 MIR675 MIR378A MIR199A1 MIR183
3	positive regulation of transcription, DNA-templated	GO:0045893	9.73	TP53 TFE3 PAX3 MYOG MYOD1 FOXO1
4	regulation of transcription, DNA-templated	GO:0006355	9.56	TP53 TFE3 PAX7 PAX3 MYOG MYOD1
5	myotube differentiation	GO:0014902	9.4	MYOG MYOD1
6	positive regulation of skeletal muscle fiber development	GO:0048743	9.37	MYOG MYOD1
7	muscle cell fate commitment	GO:0042693	9.16	MYOG MYOD1
8	muscle organ development	GO:0007517	8.92	PAX7 PAX3 MYOG MYOD1

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription factor activity, RNA polymerase II-specific	GO:0000981	9.95	TP53 TFE3 PAX7 PAX3 MYOG MYOD1
2	sequence-specific double-stranded DNA binding	GO:1990837	9.83	TFE3 PAX7 PAX3 MYOG MYOD1
3	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.8	TP53 TFE3 PAX7 PAX3 MYOG MYOD1
4	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	9.72	TP53 TFE3 MYOG MYOD1 FOXO1
5	proximal promoter sequence-specific DNA binding	GO:0000987	9.54	TP53 MYOG MYOD1
6	mRNA 3'-UTR binding	GO:0003730	9.46	TP53 MIR9-1 MIR675 MIR183
7	mRNA binding involved in posttranscriptional gene silencing	GO:1903231	9.35	MIR9-1 MIR675 MIR378A MIR199A1 MIR183
8	DNA-binding transcription factor activity	GO:0003700	9.17	TP53 TFE3 PAX7 PAX3 MYOG MYOD1

Sources

Sources for Muscle Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia